Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Clinical and Experimental Rheumatology|April 14, 2017
Adherence to guidelines for the treatment of Behçet's syndrome in New York and AmsterdamFloor G Kerstens, Franktien Turkstra, Selma Atalay, et al.Journal of Vascular Surgery. Venous and Lymphatic Disorders|March 20, 2016
Biomarkers for post-thrombotic syndromeAnnemieke C Bouman, Selma Atalay, Hugo Ten Cate, et al.Annals of Family Medicine|January 13, 2010
Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patientsFrederiek F van Doormaal, Selma Atalay, Henk J Brouwer, et al.Acta Dermato-Venereologica|April 27, 2021
Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily PracticeSelma Atalay, Lara S van der Schoot, Laura Vandermaesen, et al.BMC Dermatology|May 10, 2017
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trialSelma Atalay, Juul M P A van den Reek, Lieke J van Vugt, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 15, 2018
Deficiency of the human cysteine protease inhibitor cystatin M/E causes hypotrichosis and dry skinEllen H J van den Bogaard, Michel van Geel, Ivonne M J J van Vlijmen-Willems, et al.Acta Dermato-Venereologica|November 16, 2020
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR StudySelma Atalay, Juul M P A van den Reek, Marisol E Otero, et al.JAMA Dermatology|February 13, 2020
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical TrialSelma Atalay, Juul M P A van den Reek, Alfons A den Broeder, et al.The Journal of Dermatological Treatment|February 23, 2022
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trialSelma Atalay, Sophie E Berends, Hans M M Groenewoud, et al.Pageof 1